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 Introduction 
 Granulomatous slack skin (GSS) is an 
extremely rare disorder within the group 
of cutaneous T cell lymphomas (CTCL). In 
the WHO/EORTC classification of 2005, 
GSS is referred to as a subtype of mycosis 
fungoides (MF)  [1, 2] . GSS is typically lo-
cated in the groin or/and armpits with red, 
non-itchy, slack plaques. Histologically it 
is characterized by a CD4-positive lym-
phocytic infiltrate gathered around multi-
nuclear giant cells throughout the whole 
dermis and subcutis accompanied by 
phagocytosis of elastic fibres  [1, 3] . GSS 
and other CTCL types, in particular 
CD30-positive CTCL, may be associated 
with Hodgkin’s disease  [3] .
 The clinical course consists of an in-
flammatory stage accompanied by a dense 
and granulomatous histological infiltrate 
which induces changes in connective tis-
sue leading to the elastolytic and anetoder-
mic aspect of slack skin from which this 
disease derives its name. Therapy is tar-
geted at inflammation as well as the chang-
es in connective tissue. Established treat-
ment options for GSS (and CTCL in gen-
eral) comprise potent local steroids, 
interferon, retinoids and psoralen plus ul-
traviolet A (PUVA).
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 Abstract 
 Granulomatous slack skin (GSS) is an ex-
tremely rare disorder within the group of cu-
taneous T cell lymphomas (CTCL). Ultraviolet 
A1 (UVA1) phototherapy has previously been 
reported to be useful in the treatment of 
CTCL such as mycosis fungoides. We report 
a 35-year-old Caucasian male with GSS treat-
ed with UVA1 phototherapy starting at 20 J/
cm 2 UVA1 3 times a week and subsequently 
increased in increments of 5 J/cm 2 to a me-
dium-range dose of 50 J/cm 2 per session. 
The patient underwent a total of 45 sessions 
with a cumulative dose of 1,495 J/cm 2 UVA1 
without any adverse events. At the conclu-
sion of UVA1 phototherapy, a decrease in 
 erythema and skin thickness was observed 
which was most prominent in the periphery 
of the lesion in the right groin area. A follow-
up 12 months after phototherapy showed 
continued treatment benefit. To our knowl-
edge, this is the first report describing the 
successful use of UVA1 (340–400 nm) photo-
therapy in a patient with GSS. 
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 Ultraviolet A1 (UVA1; 340–400 nm) 
phototherapy was first described in 1981 
 [4] . It can be administered in low (10–30 
J/cm 2 ), medium (40–70 J/cm 2 ) or high dos-
es (up to 130 J/cm 2 ). UVA1 has different 
effects that may contribute to the suppres-
sion, or prevention of flares, of a variety of 
skin diseases, including its ability to in-
duce T lymphocyte apoptosis  [5] , likely be-
ing relevant in the treatment of CTCL. Its 
use has lately been documented mainly in 
atopic dermatitis  [6–8] , localized sclero-
derma  [9, 10] and in lichenoid dermatosis 
 [11] . Other diseases responding to UVA1 
phototherapy include keloids  [12] , urticar-
ia pigmentosa  [13] and systemic lupus ery-
thematosus  [14] . The value of using UVA1 
in the treatment of cutaneous lymphomas 
has also been qualified by several authors 
 [15–18] . To our knowledge, this is the first 
report describing the successful use of 
UVA1 phototherapy in GSS.
 Case Report 
 A 35-year-old Caucasian male (Fitz-
patrick skin phototype II) with unremark-
able past medical history and without 
 regular medication was referred to our 
phototherapy unit in the Department of 
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 Fig. 1. Skin biopsies taken from GSS before 
( a ) and 12 months after treatment from the 
UVA1-responding area ( b ; see fig. 2 for
location). Skin biopsies (haematoxylin-
eosin stain) demonstrate orthokeratosis 
with limited parakeratosis, and little spon-
giosis. In the upper dermis there appears a 
subepidermal, focally epidermotropic in-
filtrate of lymphocytes, mixed single his-
tiocytes and multinucleated giant cells 
with rosette-like figures. The lymphocytic 
infiltrate is more pronounced in the pre-
treatment area of GSS ( a ), while increased 
connective tissue in the upper and mid-
dermis is more pronounced in the area re-
sponding to UVA1 treatment ( b ). Details 
of epidermal and dermal GSS involvement 
before treatment are shown at magnifica-
tions of  ! 100 ( a ) and  ! 200 ( inset ).  b Hae-
matoxylin-eosin stain of UVA1-respon-
sive area depicted at a magnification of 
 ! 20. 
 Fig. 2. Clinical presentation before (left-
hand panels) and after 6 months of UVA1 
phototherapy (right-hand panels) with a 
cumulative dose of 1,495 J/cm 2 in frontal 
( a ) and right lateral ( b ) view. Note im-
provement of erythema as well as decrease 
in infiltrate reflected by more prominent 
slackness (wrinkling) of the skin most 
pronounced at the top and bottom lateral 
periphery of the lesion following 6 months 
of UVA1 phototherapy (right-hand pan-
els). Twelve months after UVA1 treatment, 
a 4-mm punch biopsy was taken from the 
UVA1-treatment-responsive area of GSS 
( b , white circle).  2 
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Dermatology with a 13-year history of red, 
well-demarcated, asymptomatic, slowly 
growing plaques on his groins. With a 4-
year delay, the diagnosis of GSS (MF stage 
IB) was established based on the typical 
clinical presentation and histology ( fig. 1 ). 
Complete blood count was repeatedly 
within normal limits. Ultrasound of lymph 
nodes and abdomen repeatedly showed 
stable, enlarged lymph nodes in the right 
groin without other anomalies, indicating 
localized disease. Chest X-ray showed no 
abnormality on several occasions.
 After having used topical emollients 
and potent topical steroids, PUVA therapy 
in combination with   -interferon was ini-
tiated because of progressive disease and 
led to partial remission  [19] . Subsequently, 
treatment was switched to intralesional   -
interferon-releasing adenovirus injections 
 [20] . Two years before UVA1 photother-
apy,      the      patient     had     been     enrolled     in  
a study protocol combining bexarotene 
(Targretin  ) and oral suberoylanilide 
 hydroxamic acid (a class of antitumour 
agents inhibiting histone deacetylase) with 
resulting mild improvement. Bexarotene 
induced hyperlipidaemia which occurred 
6 months after treatment onset and was 
therefore discontinued. Suberoylanilide 
hydroxamic acid was used as monothera-
py for another 6 months and was then 
stopped because of the patient’s wish to be-
come father.
 After a wash-out period of 1 month, 
UVA1 therapy was initiated. At the start of 
UVA1 phototherapy, the patient presented 
several large, mostly red, partly brownish 
and whitish, well-demarcated, non-tender, 
infiltrated plaques spanning the lateral 
and ventral aspect of his lower trunk 
slightly extending onto his lower extremi-
ties with most pronounced features in the 
right inguinal area and its lateral continu-
ation ( fig. 2 a and b, left-hand panels). 
Therapy was started at 20 J/cm 2 UVA1 3 
times a week and increased in increments 
of 5 J/cm 2 to a dose of 50 J/cm 2 per session 
(medium-dose UVA1 phototherapy). A 
medium-dose regimen was chosen based 
on findings from the few comparative 
studies that showed no benefit for high-
dose over medium-dose UVA1 in atopic 
dermatitis  [21, 22] and based on our cen-
tre’s experience. Incremental doses are 
part of our standard UVA1 protocol where 
we initiate therapy without previous de-
termination of the minimal erythema 
dose. The patient underwent a total of 45 
sessions with a cumulative dose of 1,495 
J/cm 2 UVA1. No adverse effects were noted 
during UVA1 phototherapy. At the con-
clusion of UVA1 phototherapy, a decrease 
in erythema and a decrease in skin thick-
ness with accompanying more prominent 
slackness (wrinkling) of the skin probably 
due to reduction of the inflammatory 
 infiltrate were observed and were most 
prominent in the periphery of the lesion in 
the right groin area ( fig. 2 a and b, right-
hand panels). A follow-up 12 months after 
phototherapy showed continued treat-
ment benefit with stable disease under 
continued use of 0.1% triamcinolone topi-
cally without flare-up of this MF variant. 
Since 0.1% triamcinolone has been used 
continuously topically 3 times/week be-
fore, during and after the UVA1 treatment, 
we suggest that the observed favourable re-
sponse is rather not due to the topical ste-
roid treatment. Nevertheless, it cannot be 
entirely excluded that, at least partially, the 
topical steroid applications contributed to 
the treatment benefit observed upon UVA1 
treatment, especially on a histological lev-
el. At this 12-month follow-up, a 4-mm 
punch biopsy from the UVA1-treatment-
responsive area was taken (histology 
shown in  fig. 1 b; biopsy location shown in 
 fig. 2 b).
 Discussion 
 Established treatment options for 
CTCL in general and GSS in particular 
comprise potent local steroids,   -interfer-
on, retinoids and PUVA, and had all been 
used in our patient with transient partial 
remission at best. Phototherapy is a widely 
used treatment option in MF in general. 
For patch stage MF, UVB 311 nm (narrow 
band) is probably the treatment of choice 
 [23–26] . PUVA is well established for MF 
and currently mostly used for plaque and 
tumour stages of MF  [27, 28] . Several au-
thors have described a benefit of UVA1 in 
cutaneous lymphomas  [7, 15–17] , but to 
our knowledge no reports of GSS treated 
with UVA1 have been published. In one 
case report  [15] , a case of MF was success-
fully treated with 60 J/cm 2 UVA1 5 times a 
week for 3 weeks (cumulative UVA dose 
900 J/cm 2 ). Plettenberg et al.  [16] used 
UVA1 phototherapy as monotherapy in 3 
patients with histologically proven MF 
(stages IA and IB). For daily whole-body 
UVA1 irradiations, either a high-dose (n = 
2; 130 J/cm 2 UVA1 per exposure) or me-
dium-dose (n = 1; 60 J/cm 2 UVA1) regimen 
was used. In all 3 patients (range of cumu-
lative UVA1 dose 960–2,600 J/cm 2 ), skin 
lesions began to resolve after only a few 
UVA1 radiation exposures. Complete 
clearance was observed between 16 and 20 
exposures (equals number of exposures), 
regardless of whether the high- or medi-
um-dose regimen had been employed. In 
another study  [17] , 13 MF patients (8 stage 
IB, 4 stage IIB and 1 stage III) received 100 
J/cm 2 UVA1 daily until remission (mean 
number of exposures 21.9; mean cumula-
tive UVA1 dose 2,148.5 J/cm 2 ). Eleven pa-
tients showed complete clinical and histo-
logical responses. Two patients had a par-
tial improvement.
 The potential advantages of UVA1 use 
over other forms of phototherapy include 
its freedom from systemic or topical pre-
treatment with psoralens combined with 
UVA’s potential for deeper penetration 
compared to UVB. UVA1 tolerability is 
high with few occurrences of treatment-
induced solar erythema, thus not inter-
rupting dose escalation. Acute adverse 
events have been observed and reported, 
including (i) erythema (despite this being 
a less erythematogenic radiation than 
broad-band UVA or UVB), (ii) brown pig-
mentation (tanning), (iii) polymorphic 
light eruption, (iv) itch and (v) reactivation 
of herpes simplex infection. Little is known 
about long-term adverse events by treating 
patients with UVA1, though. The major 
potential chronic adverse events are pho-
to-aging and skin cancer development, 
possibly comparable to PUVA which in-
cludes the controversial issue of melanoma 
induction  [29] .
 UVA1 is known to induce collagenase 
production by fibroblasts. This effect of 
UVA1 is thought to be beneficial e.g. in 
systemic sclerosis. GSS is not primarily a 
sclerosing disorder, rather one with a net 
loss of functional collagen. Over the course 
of UVA1 therapy, we observed decreased 
infiltration of the affected areas and in-
creased wrinkling. Based on clinical im-
pression and histological picture, we as-
sume that UVA1 reduced the inflamma-
tory infiltrate, thus revealing the loss of 
functional collagen by the underlying dis-
ease resulting in increased skin slackness.
 In summary, we found UVA1 photo-
therapy to be a well-tolerated and benefi-
cial treatment option in this patient and 
would thus like to suggest UVA1 photo-
therapy as additional treatment modality 
for GSS. Larger series will be needed to 
validate this observation. 
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